Nucor earnings beat by $0.08, revenue fell short of estimates
SAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), recently executed a series of stock sales amounting to $50,020, according to a filing with the Securities and Exchange Commission. The sales were conducted over two consecutive days, February 6 and 7, 2025. The biotechnology company, currently valued at $986 million, has shown mixed financial performance with a strong return over the last month despite not being profitable in the last twelve months. InvestingPro analysis reveals 7 additional key insights about GYRE’s financial position.
On February 6, Songjiang sold 2,000 shares of common stock at a weighted average price of $12.85 per share. The following day, another 2,000 shares were sold at a weighted average price of $12.16 per share. Both transactions were carried out under a Rule 10b5-1 trading plan, which was adopted on September 13, 2024. The stock currently trades at $11.57, below these transaction prices, with InvestingPro data indicating the company is trading above its Fair Value.
Following these transactions, Songjiang holds 2,879,158 shares indirectly through his spouse. The sales were executed at prices ranging from $12.16 to $13.05 per share, as part of multiple transactions. With a current ratio of 3.72, GYRE maintains strong liquidity, operating with moderate debt levels according to InvestingPro analysis.
In other recent news, Gyre Therapeutics has made significant changes to its leadership structure. The biotechnology firm announced the appointment of Ping Zhang as the lead independent director of its Board of Directors. Zhang brings a wealth of financial experience to the role, having held positions at String Capital Management, AEON Life Insurance (NSE:LIFI) Company, and Japan Asia Investment Co.
Simultaneously, the company’s indirectly owned subsidiary, Gyre Pharmaceuticals, has seen a change in chairmanship. Songjiang Ma has taken over the role from Ying Luo, who stepped down to concentrate on his responsibilities at GNI Group Ltd.
These are recent developments in the company’s ongoing efforts to advance its drug pipeline. Among the key projects is the development and commercialization of F351 (Hydronidone) for MASH-associated fibrosis in the U.S. Meanwhile, Gyre Pharmaceuticals is focusing on clinical trials for F351 and the commercialization of ETUARY® (Pirfenidone capsule) in the People’s Republic of China. ETUARY® has shown promising results as a treatment for idiopathic pulmonary fibrosis, with net sales reaching $112.1 million in 2023.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.